Short-acting beta2-agonists (SABA) are a type of bronchodilators. These are the most common immediate-relief drugs for treating asthma attacks and to manage both acute and stable exacerbations of chronic obstructive pulmonary disease (COPD). Salbutamol is the most commonly prescribed short-acting beta2-agonists (SABA) and is available under different brand names such as Salamol, Ventolin, and Proventil. The usage of short-acting beta-2-agonists SABAs on a regular basis for at least seven days in stable COPD is associated with the decrease in breathlessness and improvement in post bronchodilator lung function within 5 minutes. The inhaled form of the drug is available in metered-dose inhalers and as a liquid for compressor-driven nebulizers. Short-acting beta2-agonists (SABA) are utilized to treat symptoms in intermittent asthma, prevent asthma symptoms before exercise, and provide quick relief of symptoms during asthma attacks. A combination of ipratropium and short-acting beta2-agonists (SABA) in severe, acute asthma episodes results in improved lung function and fewer hospital visits.
Short-acting beta2 agonist (SABA) is known as a quick-acting and reliving medication from sudden asthma attacks, as it helps to rapidly open the airways. This is driving the global short acting beta2-agonists (SABA) market. Emergence of biologics to treat severe asthma and novel combination therapies are likely to drive the market. New technological advancements and product innovations lead to increased demand for the Short-acting beta2 agonist (SABA) drugs. However, the expiry of patents and exclusivity of branded drugs are restraining the market. Ability of the drug to keep asthma under control and increasing population suffering from asthma and chronic diseases such as chronic obstructive pulmonary disease are attributed to boost the global short acting beta2-agonists market. According to the World Health organization (WHO), in 2015, 383,000 people died due to asthma. Many asthma-related deaths occur in low- and lower-middle income countries. WHO also stated that approximately 235 million people are presently suffering from asthma, and it is a common disease among children.
WHO estimated that, in 2015, COPD caused 3 million deaths across the world, which accounts to approximately 5% of all deaths. The primary cause of COPD is exposure to tobacco smoke, either passive or active. Expansion of the market is attributed to the popularity and preference for short acting beta2-agonists. However, patent and exclusivity expiry of major selling drugs such as Serevent, restrains the global market. The global short-acting beta2 agonists (SABA) market can be segmented based on dosage form, application type, distribution channel, and region. Based on dosage form, the market can be segregated into solution, injectable, tablet, syrup, and elixir. In terms of the application type, the market can be segmented into Chronic Obstructive Pulmonary Disease (COPD) and asthma. Based on distribution channel, the market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies.
In terms of region, the market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held a prominent share of the market in 2016 due to technological advancements in R&D of short acting beta2-agonists drugs. Europe followed North America in terms of market share in 2016 due to the increased prevalence of asthma. According to Asthma UK, 5.4 million people in the U.K. are currently diagnosed with asthma, approximately 1.1 million children, which accounts to 1 in 11, and 4.3 million adults, which accounts 1 in 12. The market in Asia Pacific, Latin America, and Middle East & Africa is estimated to expand during the forecast period due to the increasing population and air pollution.
Key players operating in the global short acting beta2-agonists (SABA) market include Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Actelion Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, and GlaxoSmithKline plc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.